Search

Your search keyword '"Buller, Harry"' showing total 473 results
Start Over Author "Buller, Harry"
473 results on '"Buller, Harry"'

10. Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis

Author

Khan, Faizan, additional, Rahman, Alvi, additional, Tritschler, Tobias, additional, Carrier, Marc, additional, Kearon, Clive, additional, Weitz, Jeffrey I., additional, Schulman, Sam, additional, Couturaud, Francis, additional, Becattini, Cecilia, additional, Agnelli, Giancarlo, additional, Brighton, Timothy A., additional, Lensing, Anthonie W. A., additional, Pinede, Laurent, additional, Parpia, Sameer, additional, Geersing, Geert-Jan, additional, Takada, Toshihiko, additional, Bradbury, Charlotte A., additional, Andreozzi, Giuseppe M., additional, Palareti, Gualtiero, additional, Prandoni, Paolo, additional, Buller, Harry R., additional, Mallick, Ranjeeta, additional, Hutton, Brian, additional, Thavorn, Kednapa, additional, Le Gal, Gregoire, additional, Rodger, Marc A., additional, and Fergusson, Dean A., additional

Published
2021
Full Text
View/download PDF

15. Challenges in the Diagnosis Acute Pulmonary Embolism

Author

Stein, Paul D., Sostman, H. Dirk, Bounameaux, Henri, Buller, Harry R., Chenevert, Thomas L., Dalen, James E., Goodman, Lawrence R., Gottschalk, Alexander, Hull, Russell D., Leeper, Kenneth V., Jr, Pistolesi, Massimo, Raskob, Gary E., Wells, Philip S., and Woodard, Pamela K.

Published
2008
Full Text
View/download PDF

16. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage

Author

Kaandorp, Stef P., Goddijn, Mariette, van der Post, Joris, Hutten, Barbara A., Verhoeve, Harold R., Hamulyak, Karly, Mol, Ben Willem, Folkeringa, Nienke, Nahuis, Marleen, Papatsonis, Dimitri N.M., Buller, Harry R., van der Veen, Fulco, and Middeldorp, Saskia

Subjects
Aspirin -- Dosage and administration, Aspirin -- Comparative analysis, Heparin -- Dosage and administration, Heparin -- Comparative analysis, Miscarriage -- Prevention, Drug therapy, Combination
Abstract

A study was conducted to evaluate the efficacy of aspirin plus heparin or aspirin alone in reducing recurrent miscarriage among women. Results indicated that neither of the two were beneficial in reducing the incidence of recurrent miscarriage.

Published
2010

17. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy

Author

Jong, Eefje, Louw, Susan, Meijers, Joost C.M., de Kruif, Martijn D., ten Cate, Hugo, Buller, Harry R., Mulder, Jan Willem, and van Gorp, Eric C.M.

Subjects
HIV infection -- Care and treatment, HIV infection -- Physiological aspects, Antiviral agents -- Usage, Antiviral agents -- Health aspects, Homeostasis -- Research, Homeostasis -- Physiological aspects, Venous thrombosis -- Care and treatment, Venous thrombosis -- Patient outcomes, Health
Abstract

The incidence of arterial and venous thrombosis in HIV-infected patients is increased compared to healthy controls. In this cross-sectional analysis we measured markers of endothelial cell activation, thrombin generation, fibrinolysis and anticoagulation combined with endogenous thrombin potential (ETP) and activated protein C sensitivity ratio (APCsr) as more global markers. We included 160 consecutive HIV-infected patients with a median age of 46 years (range, 27-77), of whom 92% were male, 74% Caucasian, 11% African American, 9% Hispanic, and 6% Asian. Homosexual contact was the main transmission mode. Seventy percent of patients were using combined antiretroviral therapy (cART). In 83% of patients laboratory markers outside the normal range for a non-HIV-infected population were observed. Significant lower levels of von Willebrand factor (vWF; p = 0.03), factor VIII (p < 0.0001), D-dimer (p = 0.01), and ETP (p = 0.01) were observed in HIV-infected patients on cART compared to patients not on cART. Significant lower levels of protein C (p = 0.05) and free protein S (p < 0.0001), and increased APCsr (p < 0.0001) were found in the HIV-infected patients not on cART. A single association was observed between raised levels of fibrinogen and use of a protease inhibitor (p = 0.002). No significant difference was observed in the percentage of patients with laboratory markers outside the normal range between patients using cART-regimens containing abacavir, stavudine, or didanosine and those with other nucleoside reverse transcriptase inhibitors. Although the prevalence of coagulation abnormalities was lower in HIV-infected patients using cART, a considerable proportion of HIV-infected patients on cART show endothelial cell activation and increased APCsr, suggestive of a persistent procoagulant state. DOI: 10.1089/apc.2009.0173

Published
2009

18. Serial-2 point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein

Author

Cogo, Alberto, Camporese, Giuseppe, Buller, Harry R., Imberti, Davide, Berchio, Arrigo, Ghirarduzzi, Angelo, Verlato, Fabio, Anastasio, Raffaela, Prati, Carolina, Piccioli, Andrea, Pesavento, Raffaele, Bova, Carlo, Maltempi, Patrizia, Zanatta, Nello, Cappelli, Roberto, Bucherini, Eugenio, Cuppini, Stefano, Noventa, Franco, and Prandoni, Paolo

Subjects
Venous thrombosis -- Diagnosis, Venous thrombosis -- Care and treatment, Ultrasound imaging -- Usage, Ultrasound imaging -- Health aspects
Abstract

A study was conducted to investigate whether 2 diagnostic strategies are the same for management of symptomatic outpatients with suspected Deep vein thrombosis (DVT) of the lower extremities. Results indicated that 2 diagnostic strategies were equivalent for management of symptomatic outpatients with suspected DVT of lower extremities.

Published
2008

20. Extended prophylaxis of venous thromboembolism with idraparinux

Author

Buller, Harry R., Cohen, Ander T., Davidson, Bruce, Decousus, Herve, Gallus, Alex S., Gent, Michael, Pillion, Gerard, Piovella, Franco, Prins, Martin H., and Raskob, Gary E.

Subjects
Thrombophlebitis -- Risk factors, Hemorrhage -- Risk factors, Vitamin K -- Health aspects
Abstract

The efficiency and the safety of a continuous use of vitamin K for prophylaxis against the venous thromboembolism with idraparinux in various patients were examined. The results showed that though idraparinux helps in preventing recurrent thromboembolism, it also increases the risks of a major hemorrhage.

Published
2007

21. Idraparinux versus standard therapy for venous thromboembolic disease

Author

Buller, Harry R., Cohen, Ander T., Davidson, Bruce, Decousus, Herve, Gal, Alex S., Gent, Michael, Pillion, Gerard, Piovella, Franco, Prins, Martin H., and Raskob, Gary E.

Subjects
Thrombophlebitis -- Drug therapy, Anticoagulants (Medicine) -- Health aspects
Abstract

The use of idraparinux, a long-acting inhibitor of activated factor X, instead of the standard therapy of treating the venous thromboembolic disease is investigated. The analysis reveals that idraparinux is less effective than the standard therapy for patients with pulmonary embolism.

Published
2007

22. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations

Author

Kuipers, Saskia, Cannegieter, Suzanne C., Middeldorp, Saskia, Robyn, Luc, Buller, Harry R., and Rosendaal, Frits R.

Subjects
Air travel -- Canada, Air travel -- Health aspects, Aircraft industry workers -- Health aspects, Aircraft industry workers -- Research, Thrombophlebitis -- Risk factors, Thrombophlebitis -- Research
Abstract

ABSTRACT Background The risk of venous thrombosis is approximately 2- to 4-fold increased after air travel, but the absolute risk is unknown. The objective of this study was to assess [...]

Published
2007

23. Direct thrombin inhibitors

Author

Nisio, Marcello Di, Middeldorp, Saskia, and Buller, Harry R.

Subjects
Coronary heart disease -- Drug therapy, Anticoagulants (Medicine) -- Evaluation, Anticoagulants (Medicine) -- Usage
Abstract

Four parenteral direct thrombin inhibitors (DTIs), which constitute a new group of anticoagulants, sanctioned by the Food and Drug Administration (FDA) in North America are examined. Conclusions reveal that no DTIs have substantially proved to be effective and safe for prolonged treatment following severe coronary syndromes.

Published
2005

24. Efficacy and safety of statin therapy in children with familial hypercholesterolemia

Author

Wiegman, Albert, Buller, Harry R., Hutten, Barbara A., Sijbrands, Eric J. G., Groot, Eric de, Kastelein, John J. P., Rodenburg, Jessica, and Bakker, Henk D.

Subjects
Statins -- Dosage and administration, Statins -- Evaluation, Hypercholesterolemia in children -- Risk factors
Abstract

The children with hypercholesterolemia have endothelial dysfunction with increased carotid intima-media thickness (IMA), which cause premature atherosclerotic disease, hence studies were conducted to check the efficacy as well as safety of statin therapy in such children. It was found that two years of pravastatin therapy caused a significant amount of reduction of carotid atherosclerosis in children with no adverse effects on growth.

Published
2004

34. Safely ruling out deep venous thrombosis in primary care

Author

Buller, Harry R., ten Cate-Hoek, Arina J., Hoes, Arno W., Joore, Manuela A., Moons, Karel G.M., Oudega, Ruud, Prins, Martin H., Stoffers, Henri E.J.H., Toll, Diane B., van der Velde, Eit F., and van Weert, Henk C.P.M.

Subjects
Venous thrombosis -- Diagnosis, Venous thrombosis -- Care and treatment, Health
Abstract

Background: Up to 90% of patients referred for ultrasonography with suspected deep venous thrombosis (DVT) of the leg do not have the disease. Objective: To evaluate the safety and efficiency of using a clinical decision rule that includes a point-of-care D-dimer assay at initial presentation in primary care to exclude DVT. Design: A prospective management study. Setting: Approximately 300 primary care practices in 3 regions of the Netherlands (Amsterdam, Maastricht, and Utrecht). Patients: 1028 consecutive patients with clinically suspected DVT. Intervention: Patients were managed on the basis of the result of the clinical decision rule, which included a D-dimer result. Patients with a score of 3 or less were not referred for ultrasonography and received no anticoagulant treatment; patients with a score of 4 or more were referred for ultrasonography. Measurements: The primary outcome was symptomatic, objectively confirmed, venous thromboembolism during 3-month follow-up. Results: The mean age of the 1028 study patients was 58 years, and 37% of patients were men. A valid score was obtained in 1002 patients (98%). In 500 patients (49%), with a score of 3 or less, 7 developed venous thromboembolism within 3 months (incidence, 1.4% [95% CI, 0.6% to 2.9%]). A total of 502 patients (49%) had a score of 4 or more; 3 did not have ultrasonography. Ultrasonography showed DVT in 125 patients (25%), for an overall prevalence in evaluable patients of 13% (125 of 1002). Of the 374 patients who had normal ultrasonography results, 4 developed venous thromboembolism within 3 months (1.1% [CI, 0.3% to 2.7%]). Limitation: The study lacked a randomized design and relied on clinical follow-up to detect missed thrombotic disease. Conclusion: A diagnostic management strategy in primary care by using a simple clinical decision rule and a point-of-care D-dimer assay reduces the need for referral to secondary care of patients with clinically suspected DVT by almost 50% and is associated with a low risk for subsequent venous thromboembolic events. Funding: The Netherlands Organization for Scientific Research.

Published
2009

35. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study

Author

Nijkeuter, Mathilde, Sohne, Maaike, Tick, Lidwine W., Kamphuisen, Pieter Willem, Kramer, Mark H.H., Laterveer, Laurens, van Houten, Anja A., Kruip, Marieke J.H.A., Leebeek, Frank W.G., Buller, Harry R., and Huisman, Menno V.

Subjects
Pulmonary embolism -- Research, Pulmonary embolism -- Risk factors, Pulmonary embolism -- Development and progression, Outcome and process assessment (Health Care) -- Research, Outcome and process assessment (Health Care) -- Health aspects, Mortality -- Evaluation, Mortality -- Causes of, Health
Published
2007

37. Thrombo-Inflammation in Cardiovascular Disease : An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis

Author

d'Alessandro, Elisa, Becker, Christian, Bergmeier, Wolfgang, Bode, Christoph, Bourne, Joshua H., Brown, Helena, Buller, Harry R., ten Cate-Hoek, Arina J., ten Cate, Vincent, van Cauteren, Yvonne J. M., Cheung, Yam F. H., Cleuren, Audrey, Coenen, Danielle, Crijns, Harry J. G. M., de Simone, Ilaria, Dolleman, Sophie C., Klein, Christine Espinola, Fernandez, Delia I., Granneman, Lianne, van t Hof, Arnoud, Henke, Peter, Henskens, Yvonne M. C., Huang, Jingnan, Jennings, Lisa K., Jooss, Natalie, Karel, Mieke, van den Kerkhof, Danique, Klok, Frederik A., Kremers, Bram, Laemmle, Bernhard, Leader, Avi, Lundstrom, Annika, Mackman, Nigel, Mannucci, Pier M., Maqsood, Zahra, van der Meijden, Paola E. J., van Moorsel, Marc, Moran, Luis A., Morser, John, van Mourik, Manouk, Navarro, Stefano, Neagoe, Raluca A. I., Olie, Renske H., van Paridon, Pauline, Posma, Jens, Provenzale, Isabella, Reitsma, Pieter H., Scaf, Billy, Schurgers, Leon, Seelig, Jaap, Siegbahn, Agneta, Siegerink, Bob, Soehnlein, Oliver, Soriano, Eva Maria, Sowa, Marcin A., Spronk, Henri M. H., Storey, Robert F., Tantiwong, Chukiat, Veninga, Alicia, Wang, Xueqing, Watson, Steve P., Weitz, Jeff, Zeerleder, Sacha S., ten Cate, Hugo, Lina, Badimon, Christoph, Binder, Marc, Hoylaerts, Peter, Karlheinz, GregoryLip, Koenen Rory, Steffen, Massberg, Philipp, von Hundelshausen, Christian, Weber, Johann, Wojta, d'Alessandro, Elisa, Becker, Christian, Bergmeier, Wolfgang, Bode, Christoph, Bourne, Joshua H., Brown, Helena, Buller, Harry R., ten Cate-Hoek, Arina J., ten Cate, Vincent, van Cauteren, Yvonne J. M., Cheung, Yam F. H., Cleuren, Audrey, Coenen, Danielle, Crijns, Harry J. G. M., de Simone, Ilaria, Dolleman, Sophie C., Klein, Christine Espinola, Fernandez, Delia I., Granneman, Lianne, van t Hof, Arnoud, Henke, Peter, Henskens, Yvonne M. C., Huang, Jingnan, Jennings, Lisa K., Jooss, Natalie, Karel, Mieke, van den Kerkhof, Danique, Klok, Frederik A., Kremers, Bram, Laemmle, Bernhard, Leader, Avi, Lundstrom, Annika, Mackman, Nigel, Mannucci, Pier M., Maqsood, Zahra, van der Meijden, Paola E. J., van Moorsel, Marc, Moran, Luis A., Morser, John, van Mourik, Manouk, Navarro, Stefano, Neagoe, Raluca A. I., Olie, Renske H., van Paridon, Pauline, Posma, Jens, Provenzale, Isabella, Reitsma, Pieter H., Scaf, Billy, Schurgers, Leon, Seelig, Jaap, Siegbahn, Agneta, Siegerink, Bob, Soehnlein, Oliver, Soriano, Eva Maria, Sowa, Marcin A., Spronk, Henri M. H., Storey, Robert F., Tantiwong, Chukiat, Veninga, Alicia, Wang, Xueqing, Watson, Steve P., Weitz, Jeff, Zeerleder, Sacha S., ten Cate, Hugo, Lina, Badimon, Christoph, Binder, Marc, Hoylaerts, Peter, Karlheinz, GregoryLip, Koenen Rory, Steffen, Massberg, Philipp, von Hundelshausen, Christian, Weber, and Johann, Wojta

Abstract

Thrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating cells and thrombo-inflammation, focused on platelets, neutrophils, and neutrophil extracellular traps; (3) procoagulant mechanisms; (4) arterial vascular changes in atherogenesis; attenuating atherosclerosis and ischemia/reperfusion injury; (5) management of patients with arterial vascular disease; and (6) pathogenesis of venous thrombosis and late consequences of venous thromboembolism.

Published
2020
Full Text
View/download PDF

41. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home

Author

Koopman, Maria M.W., Prandoni, Paolo, Piovella, Franco, Ockelford, Paul A., Brandjes, Desiderius P.M., Meer, Jan van der, Gallus, Alexander S., Simonneau, Gerald, Chesterman, Colin H., Prins, Martin H., Bossuyt, Patrick M.M., Haes, Hanneke de, Belt, Angelique G.M. van den, Sagnard, Luc, d'Azemar, Pascal, and Buller, Harry R.

Subjects
Venous thrombosis -- Drug therapy, Heparin -- Health aspects
Abstract

Low-molecular-weight heparin appears to offer safe and effective home treatment for deep leg vein clots. Researchers randomly assigned 400 patients with proximal deep-vein clots and no other complications to either the traditional in-hospital intravenous treatment with standard heparin or twice-daily injections of low-molecular-weight heparin administered by the patient or a family member at home. Questionnaires assessed quality of life. During the 24-week follow-up period, 9% of the hospital group versus 7% of the home treatment group experienced a recurrent, symptom-causing clot. Two percent of patients in the hospital group had a hemorrhage versus 0.5% of the home treatment group. Fifteen patients in the hospital group versus 27 patients in the home treatment group had minor bleeding. The hospital group averaged 8 days in the hospital versus 3 days for the home treatment group. The home treatment group scored higher in physical activity and social functioning.

Published
1996

44. Estimates of risk of venous thrombosis during pregnancy and puerperium are not influenced by diagnostic suspicion and referral basis

Author

Melis, Floortje, Vandenbrouke, Jan P., Buller, Harry R., Colly, Louisa P., and Bloemenkamp, Kitty W.M.

Subjects
Puerperium -- Risk factors, Pregnancy -- Risk factors, Thrombophlebitis -- Diagnosis, Thrombophlebitis -- Causes of, Health
Abstract

The purpose of this study was to determine the relative risk of deep vein thrombosis (DVT) during pregnancy and puerperium in a setting that was not influenced by diagnostic suspicion and referral bias. Show that previous studies were less affected by diagnostic suspicion and referral bias than presumed.

Published
2004

45. Antithrombotic therapy for venous thromboembolic disease

Author

Buller, Harry R., Agnelli, Giancarlo, Hull, Russel D., Hyers, Thomas M., Prins, Martin H., and Raskob, Gary E.

Subjects
Thrombophlebitis -- Care and treatment -- Research -- Risk factors, Lung diseases -- Risk factors -- Care and treatment -- Research, Thrombolytic drugs -- Research, Health, Care and treatment, Research, Risk factors
Abstract

This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and [...]

Published
2004

49. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

Author

Buller, Harry R., Davidson, Bruce L., Decousus, Herve, Gallus, Alexander, Gent, Michael, Piovella, Franco, Prins, Martin H., Raskob, Gary, Segers, Annelise E.M., Cariou, Roger, Leeuwenkamp, Oscar, and Lensing, Anthonie W.A.

Subjects
Venous thrombosis -- Drug therapy, Enoxaparin -- Dosage and administration, Enoxaparin -- Research, Health
Abstract

Background: The current standard initial therapies for deep venous thrombosis are low-molecular-weight heparin and unfractionated heparin. In a dose-ranging study of patients with symptomatic deep venous thrombosis, fondaparinux had efficacy and a safety profile similar to those of low-molecular-weight heparin (dalteparin). Objective: To evaluate whether fondaparinux has efficacy and safety similar to those of enoxaparin in patients with deep venous thrombosis. Design: Randomized, double-blind study. Setting: 154 centers worldwide. Patients: 2205 patients with acute symptomatic deep venous thrombosis. Intervention: Fondaparinux, 7.5 mg (5.0 mg in patients weighing 100 kg) subcutaneously once daily, or enoxaparin, 1 mg/kg of body weight, subcutaneously twice daily for at least 5 days and until vitamin K antagonists induced an international normalized ratio greater than 2.0. Measurements: The primacy efficacy outcome was the 3-month incidence of symptomatic recurrent venous thromboembolic complications. The main safety outcomes were major bleeding during initial treatment and death. An independent, blinded committee adjudicated all outcomes. Results: 43 (3.9%) of 1098 patients randomly assigned to fondaparinux had recurrent thromboembolic events compared with 45 (4.1%) of 1107 patients randomly assigned to enoxaparin (absolute difference, -0.15 percentage point [95% CI, -1.8 to 1.5 percentage points]). Major bleeding occurred in 1.1% of patients receiving fondaparinux and 1.2% of patients receiving enoxaparin. Mortality rates were 3.8% and 3.0%, respectively. Limitations: Follow-up was incomplete in 0.4% of fondaparinux-treated patients and 1.0% of enoxaparin-treated patients. Conclusions: Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results